| HOME >> BIOLOGY >> TECHNOLOGY |
common share under GAAP because inclusion thereof would be
antidilutive.
(l) Included in the weighted average diluted common shares for the
calculation of diluted net income per common share for the year
ended December 31, 2007, on an adjusted cash basis, are dilutive
shares consisting of 2,726,000 common stock equivalent shares from
the potential exercise of stock options and awards and warrants.
The diluted net income per common share calculation for the year
ended December 31, 2007, on an adjusted cash basis, does not
include 1,807,000 common stock equivalent shares from the potential
conversion of convertible debt, as inclusion thereof would be
antidilutive.
(m) Included in the weighted average diluted common shares for the
calculation of diluted net income per common share for the year
ended December 31, 2006, on an adjusted cash basis, are dilutive
shares consisting of 1,469,000 common stock equivalent shares from
the potential exercise of stock options and warrants.
Inverness Medical Innovations, Inc. and Subsidiaries
Condensed Consolidated Balance Sheets
(in $000s)
December 31, December 31,
2007 2006
ASSETS
CURRENT ASSETS:
Cash and cash equivalents $414,732 $71,104
Restricted cash 141,869 -
Marketable securities 2,551 -
Accounts receivable, net 163,380 100,388
Inventories, net 148,231 78,322
Prepaid expenses
'/>"/>
| SOURCE Inverness Medical Innovations Copyright©2008 PR Newswire. All rights reserved |